Abstract:OBJECTIVE: To study changes in the expression levels of parvalbumin (PV), glutamate decarboxylase 67 (GAD67) and K+-Cl- cotransporter 2 (KCC2) in the brain tissue of rats with schizophrenia (SZ) induced by dizocilpine (MK-801), and to investigate the mechanism involving gamma-aminobutyric acid (GABA) by which NMDA receptor blocker induces SZ in the perinatal period. METHODS: Thirty-six neonatal male Sprague-Dawley rats were randomly assigned to two batches on postnatal day 6. Each batch was divided into normal control (treated by 0.9% normal saline), SZ-development model (treated by subcutaneous injection of 0.1 mg/kg MK-801 on postnatal days 7-10; bid), and SZ-chronic medication model groups (treated by intraperitoneal injection of 0.2 mg/kg MK-801 on postnatal days 47-60; qd). On postnatal day 63, the brain tissue of the first batch of rats was obtained and then fixed with paraform for histological sections; expression levels of PV and GAD67 in the medial prefrontal cortex (mPFC) and hippocampus CA1 were measured by immunohistochemistry. Simultaneously, the second batch of rats was sacrificed and the mPFC and hippocampus were obtained and homogenized; expression levels of KCC2 in the mPFC and hippocampus were measured by Western blot. RESULTS: Expression levels of PV and GAD67 in the mPFC and hippocampus CA1 were significantly lower in the SZ-development and chronic medication model groups than in the normal control group (P<0.05). Expression levels of KCC2 in the mPFC and hippocampus were significantly lower in the SZ-development model group than in the SZ-chronic medication model and normal control groups (P<0.05).ConclusionsThe expression changes of PV and GAD67 in SZ can be simulated using the SZ development model induced by MK-801, which might affect the development of the GABA system in the PFC and hippocampus by downregulating KCC2 expression.
LIU Yong,TANG Ya-Mei,ZHANG Xiang-Hui et al. Changes in expression levels of PV, GAD67 and KCC2 in the brain tissue of rats with schizophrenia induced by MK-801[J]. CJCP, 2012, 14(11): 869-874.
[1]Mouri A, Noda Y, Enomoto T, Nabeshima T. Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment[J]. Neurochem Int, 2007, 51(2-4): 173-184.
[3]Zhang ZJ, Reynolds GP. A selective decrease in the relative density of parvalbumin immunoreactive neurons in the hippocampus in schizophrenia[J]. Schizophr Res, 2002, 55(1-2): 1-10.
[5]Pellegrino C, Gubkina O, Schaefer M, Becq H, Ludwig A, Mukhtarov M, et al. Knocking down of the KCC2 in rat hippocampal neurons increases intracellular chloride concentration and compromises neuronal survival[J]. J Physiol, 2011, 589(Pt 10): 2475-2496
[6]Stefani MR, Moghaddam B. Transient N-methyl-D-aspartate receptor blockade in early development causes lasting cognitive deficits relevant to schizophrenia[J]. Biol Psychiatry, 2005, 57(4): 433-436.
[7]Rujescu D, Bender A, Keck M, Hartmann AM, Ohl F, Raeder H, et al. A pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities[J]. Biol Psychiatry, 2006, 59(8):721-729.
[9]Hagberg H, Gressens P, Mallard C. Inflammation during fetal and neonatal life: implications for neurologic and neuropsychiatric disease in children and adults[J]. Ann Neurol, 2012, 71(4): 444-457.
[11]Wedzony K, Fijal K, Mackowiak M, Chocyk A, Zajaczkowski W. Impact of postnatal blockade of N-methyl-D-aspartate receptors on rat behavior: a search for a new developmental model of schizophrenia[J]. Neuroscience, 2008, 153(4): 1370-1379.
[13]Reynolds GP, Abdul-Monim Z, Neill JC, Zhang ZJ. Calcium binding protein markers of GABA deficits in schizophrenia—postmortem studies and animal models[J]. Neurotox Res, 2004, 6(1): 57-61.
[14]Romón T, Mengod G, Adell A. Expression of parvalbumin and glutamic acid decarboxylase-67 after acute administration of MK-801. Implications for the NMDA hypofunction model of schizophrenia[J]. Psychopharmacology (Berl), 2011, 217(2): 231238.
[15]Abekawa T, Ito K, Nakagawa S, Koyama T. Prenatal exposure to an NMDA receptor antagonist, MK-801 reduces density of parvalbumin-immunoreactive GABAergic neurons in the medial prefrontal cortex and enhances phencyclidine-induced hyperlocomotion but not behavioral sensitization to methamphetamine in postpubertal rats[J]. Psychopharmacology (Berl), 2007, 192(3): 303-316.
[16]Woo TU, Walsh JP, Benes FM. Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder[J]. Arch Gen Psychiatry, 2004, 61(7): 649-657.
[17]Paulson L, Martin P, Persson A, Nilsson CL, Ljung E, Westman-Brinkmalm A, et al. Comparative genome-and proteome analysis of cerebral cortex from MK-801-treated rats[J]. J Neurosci Res, 2003, 71(4): 526-533.
[18]Rivera C, Voipio J, Payne JA, Ruusuvuori E, Lahtinen H, Lamsa K, et al. The K+/Cl-co-transporter KCC2 renders GABA hyperpolarizing during neuronal maturation[J]. Nature, 1999, 397(6716): 251-255.
[19]Rivera C, Voipio J, Kaila K. Two developmental switches in GABAergic signalling: the K+-Cl-cotransporter KCC2 and carbonic anhydrase CAVII[J]. J Physiol, 2005, 562(Pt 1): 27-36.
[20]du Bois TM, Huang XF. Early brain development disruption from NMDA receptor hypofunction: relevance to schizophrenia[J]. Brain Res Rev, 2007, 53(2): 260-270.